Richter-Helm BioTec is the owner of the biosimilar teriparatide and has numerous licensing partners worldwide, including pharmaceutical companies such as STADA, Daewon, Mochida and Gedeon Richter (for 2024).
History
2024: Purchase of a 50% stake in Richter-Helm BioTec by Gedeon Richter
Gedeon Richter has signed an agreement with German stock corporation HELM AG to buy a 50% stake in Richter-Helm BioTec (RHT) and a 30% stake in Richter-Helm BioLogics (RHB), making Gedeon Richter the 100% owner of both companies. This was announced to Zdrav.Expert on March 14, 2024 by representatives of Gedeon Richter. Read more here.
Under the terms of the agreement, Gedeon Richter will pay €40.6 million for HELM's stake in Richter-Helm BioLogics and €71.8 million for its stake in Richter-Helm BioTec. In addition to €71.8 million, Gedeon Richter will transfer additional performance payments to Richter-Helm BioTec during 2025-2029.
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |